Deals
Ginkgo Bioworks Exploring Over $20 Billion Sloan SPAC Deal
- Hollywood veteran Harry Sloan took DraftKings, Skillz public
- Ginkgo may rank as one of biggest blank-check deals on record
This article is for subscribers only.
Ginkgo Bioworks, a company that designs organisms that can treat liver disorders or recreate the scent of an extinct Hawaiian hibiscus, is considering going public through a merger with a blank-check company backed by Harry Sloan, people with knowledge of the matter said.
Boston-based Ginkgo is exploring a potential combination with Soaring Eagle Acquisition Corp., said the people, who asked not to be identified because the talks are private. A transaction could be valued at more than $20 billion, the people said.